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Abstract
Background. The cost effectiveness of a general practice-based program for managing coronary heart disease (CHD)
patients in Australia remains uncertain. We have explored this through an economic model.
Methods. A secondary prevention program based on initial clinical assessment and 3 monthly review, optimising
of pharmacotherapies and lifestyle modification, supported by a disease registry and financial incentives for quality of
care and outcomes achieved was assessed in terms of incremental cost effectiveness ratio (ICER), in Australian dollars
per disability adjusted life year (DALY) prevented.
Results. Based on 2006 estimates, 263 487 DALYs were attributable to CHD in Australia. The proposed program
would add $115 650 000 to the annual national heath expenditure. Using an estimated 15% reduction in death and disability
and a 40%estimated program uptake, the program’s ICER is $8081 perDALYprevented.Withmore conservative estimates
of effectiveness and uptake, estimates of up to $38 316 per DALY are observed in sensitivity analysis.
Conclusions. Although innovation in CHDmanagement promises improved future patient outcomes, many therapies
and strategies proven to reducemorbidity andmortality are available today.Ageneral practice-based program for the optimal
application of current therapies is likely to be cost-effective and provide substantial and sustainable benefits to the
Australian community.
What is known about this topic? Chronic disease management programs are known to provide gains with respect to
reductions in death and disability among patients with coronary heart disease. The cost effectiveness of such programs in
the Australian context is not known.
What does this paper add? This paper suggests that implementing a coronary heart disease program in Australia is
highly cost-effective across a broad range of assumptions of uptake and effectiveness.
What are the implications for practitioners? These data provide the economic rationale for the implementation of
a chronic disease management program with a disease registry and regular review in Australia.
Additional keywords: coronary heart disease management programs, coronary heart disease prevention.
Introduction
Improved medical therapies and an increased use of coronary
revascularisation have been associated with a decline in the
acute mortality associated with acute coronary syndromes.
However, the burden of chronic coronary heart disease (CHD)
and other forms of cardiovascular disease remains high, with
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CHD and stroke as the two leading single causes of death in
Australia.1
Clinical research is rich in evidence documenting the
robust benefits of lifestyle and pharmacologic interventions
for people with CHD.2–5 However, both international and local
studies demonstrate that the application of these therapies is
incomplete, and persistence of therapy is suboptimal.6,7
Therefore, a key strategic approach to improve the health and
wellbeing of Australians living with CHD is to target the
evidence–management gap by providing national supports and
incentives to optimise the delivery of proven therapies and the
achievement of treatment goals among these complex patients.
Such an approach may be of particular benefit to populations
which carry a greater CHD burden; specifically Aboriginal and
Torres Strait Islander populations (who in 2000–02 died from
CHD at 2.6 times the rate of other Australians8) and rural and
regional populations, where rates of death from cardiovascular
disease appear to be higher than in urban areas, and access to
specialisedmedical services is more difficult.9
This type of initiative has been successfully implemented in
diabetes, asthma and mental health management, immunisation
and cervical cancer screening. To date, there has been no
equivalent level of recognition for CHD care that is accessible
to all general practices, although the Australian Primary Care
Collaboratives is a positive initiative that has enhanced CHD
care in several participating practices (see http://www.apcc.org.
au, accessed 2009).
Important considerations in the development of any national
program for CHD will be the potential impact on morbidity and
mortality, combined with the likely cost-burden faced by the
Australian taxpayer. To address these questions we sought to
design and economically model a general practice-based chronic
disease management program for patients with CHD.
Methods
An exploratory economic appraisal was undertaken, comparing
the additional ‘net cost’ of the proposal (i.e. gross cost of the
intervention minus anticipated cost offsets), with the attributable
health benefits measured as quality adjusted life years. Costs and
outcomes were assessed from a ‘health sector perspective’, but
with a primary focus on ‘government as third party funder’. The
analysis was undertaken using 2006 as the reference year, with a
3% discount rate applied to costs and health gains received in
future years.
Proposed program
Key design features of the ‘General Practice-based CHD
initiative’ include the establishment of practice-specific patient
registers of CHD patients with recall mechanisms and provision
of ‘cycles’ of assessment and care as outlined in Fig. 1. Specific
interventions would focus on the initiation and maintenance
of lifestyle changes, the quality use of guideline-advocated
therapies, promotion of self-care and consideration of
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Fig. 1. Consultation and financial incentive elements of CHD initiative.
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psychosocial needs. This multi-faceted approach is described
in Table 1.
Following an initial assessment, review consultations occur
every 3 months, with a reassessment at 12 months. This initiative
would be supported by existing reimbursements for each of the
consultations, as well as the introduction of financial incentives
for maintenance of a data system addressing quality of care
indicators and achievement of clinical outcomes.
Key contributors to the cost-effectiveness of such a program
are: (i) the local burden of CHD morbidity and mortality; (ii) the
health benefits achieved by the program; (iii) the uptake of the
program; (iv) the costs of implementation; and (v) the likely cost
offsets associated with the health benefits.
Burden of CHD in Australia
DALYs (disability adjusted life years) are a useful measure of
health outcomes because they combine a measure for premature
death (years of life lost, YLLs) and a measure of morbidity
(years lived with disability, YLDs). Although DALYs
originated as a descriptive measure (a summary measure of
population health), they are now commonly used as an
outcome measure in economic evaluations, because they are
available based on consistent methods across a comprehensive
range of diseases, illnesses and risk factors.10 Table 2 describes
the CHD burden on which this analysis is based.
Program benefits
The estimated benefits of the initiative described have been
derived from several sources, and include an assessment of
the burden of CHD, the likely ‘effectiveness’ of the intervention
and the anticipated uptake or reach of the program. In
combination, these estimates enable a calculation of the ‘impact’
or total absolute benefit of the program. The estimation of
‘effectiveness’ was based on a systematic review that reported
a 16% reduction in admissions to hospital, a 6% reduction in
recurrent Myocardial Infarction (MI) and a 9% reduction in
all cause mortality associated with multidisciplinary CHD
management programs,11 whereas the National Health Priority
Areas Report indicated a 15% reduction in coronary events and
a 17% reduction in coronary deaths was possible with improved
interventions for patients with CHD.12 Therefore, a 15%
reduction in DALYs, premature deaths and rehospitalisation
was used in this analysis, with more pessimistic variations of 10,
7.5 and 5% run as a sensitivity analysis. The lower effectiveness
assumptions were chosen to give an illustrative range of
more pessimistic values, rather than to reflect specific trial
evidence.
Estimates of uptake
Estimation of the program’s reach was based on assumptions
made regarding the proportions of patients with CHD visiting a
general practitioner (GP), GPs willing to undertake the program,
patients participating in the program and those patients
completing the program (as detailed in Table 2). Estimates of
uptake were derived from similar ‘Practice Incentive Programs’
for diabetes, asthma, and cervical cancer screening.13 For these
parameters, ‘low’, ‘medium’ and ‘high’ rates were estimated,
with themediumvalues used in the base-case analysis. It was also
assumed that only full completion of the program would be
associated with incremental benefits of reduction in premature
CHD deaths and DALYs.
Estimates of cost
Costs assessed in the program include: (i) the financial
incentives to facilitate general practice participation and
rewarding of quality care; (ii) payment for annual cycles of
consultations; and (iii) the effects on the health care system of
improved quality of care (reduced hospital admissions and
increased pharmaceutical, pathology, imaging and medical
service costs). These costs are presented in Table 2.
Potential cost offsets resulting from a reduction in clinical
eventswerediscountedand lagged to account for thenatural delay
in program benefits. Additional costs such as time and costs of
patient and carer travel, increased utilisation of allied health
professionals, and the opportunity cost of less time in general
practice for the treatment of other conditions were not assessed in
this model. Furthermore, no attempt has been made to assess the
impact of the proposal on the broader economy as a result of
improved productivity.
Analysis and sensitivity analysis
The cost-effectiveness of the program was calculated as the
projected net cost of the program divided by the projected
DALYs prevented (see equation). All projected costs and
benefits were discounted by 3% per annum to adjust for time
preference (when costs are paid and benefits are received) and are
expressed in real Australian dollars (to account for the impact of
inflation), with 2006 as the reference year. An incremental cost-
effectiveness ratio of <$50 000 per DALY prevented was
considered as the ‘acceptable’ threshold within the Australian
health care perspective.
‘Cost effectiveness’ðincremental cost effectiveness ratio ½ICERÞ
¼ net cost ð$Þ=net benefits ðDALYs preventedÞ
The intervention was modelled using ‘steady-state’ analysis,
whereby the intervention was assumed to be fully implemented
Table 1. Proposed general practice-based CHD initiative
Key components
Initial and ongoing
assessment
Disease risk: diabetes, hypertension and
dyslipidaemia, and obesity
Lifestyle and behavioural risks (smoking, alcohol,
nutrition and physical activity)
Psychosocial risk: depression and social isolation
Develop care and self-
management plan
Medical plan (aspirin, statin, b-blockers,
clopidogrel, ±ACE-inhibition) with assessment
of dosing, monitoring and compliance
Lifestyle and behavioural interventions
Depression management
Social supports
Referral to other health- Nurse-led secondary prevention clinics
care settings Cardiac Rehabilitation Programs
Specialist Cardiologist consultation
Data collection Quality of care indicators
Achievement of therapeutic goals
Clinical outcomes
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nation-wide, and operating in accordance with its efficacy/
effectiveness potential. The gross costs of one representative
year of ‘steady-state’ operation (2006) were compared with the
anticipated health gains for CHD patients and associated cost
offsets (lagged to reflect the anticipated year of receipt). This
assumption was made to simplify the analysis and in recognition
of the fact that the achievement of ongoing benefits for our
2006 cohort of CHD patients would be matched by ongoing
expenditures (i.e. ongoing consultations and financial incentives
to GPs).
In order to test the impact of several key assumptions,
variances in several estimates were also tested in the model
(refer Table 2). These included:
1. Higher and lower rates of ‘reach’ of the program (and
associated costs), resulting from variations in the rates of:
* patients seen by GPs;
* GPs involved in the scheme;
* patient participation and completion of the program.
2. Lower estimated rates of program effectiveness representing
more conservative estimates of program benefits and cost
offsets.
Results
Estimated burden of disease
Using 2003 estimates of incident cases and prevalence of CHD,
the estimated YLDs resulting from CHD were 45 344, YLLs
were 218 143 and DALYs were 263 487. This last figure
represents 10% of the total DALYs identified in the Australian
burden of disease study.14
Table 2. Key assumptions
DALY, disability adjusted life year; YLD, year lived with disability (calculated for incident cases and for
prevalent cases)
Value Range
CHD burden14
Total DALYs due to CHD in Australia 2006A 263 487
Total YLDs due to CHD in Australia 2006A 45 344
Total deaths due to CHD in Australia 2006A 28 207
Program uptake
Patients who visit a GP each yearB 90% 85–100%
GPs likely to participate in schemeC 75% 60–80%
Patients who accept GP invitation to participateD 80% 70–90%
Patients attending full cycle of careE 70% 50–90%
Cumulative patient ‘reach’ for estimation of outcomes 40% 21–65%
Effectiveness11,12
Reduction in CHD premature deaths 15% 5–15%
Reduction in CHD DALYs 15% 5–15%
Costs
Initial Assessment (CDM item 721) $122.40
3 and 9 month review consultation (level B consultation) $31.45
6 and 12 month review of care plan (CDM item 725) $61.20
Sign-on payment for practice CHD register/recall system $1000 per GP
Service incentive payment for completing cycle of care $40.00
Quality outcome payment for achieving specified targets
of coverage or quality outcomesF
$7.44million
Infra-structural payments to Divisions to facilitate GP
participation in CHD initiativeF
$4.08million
Increase in pharmaceutical costs 50%
Increase in pathology and imaging costs 15% 5–15%
Decrease in hospitalisation costs 15% 5–15%
AEstimates for 2003 taken as the estimate for our reference year of 2006.
B‘High’ estimate assumes all CHD patients will see a GP at least once a year, as they have an important life
threatening disease. ‘Low’ estimate assumes CHD patients will see a GP at the same rate as the general
population (i.e. 85%) based on the BEACH28 database. ‘Medium’ or most likely estimate is set between these
two logical endpoints.
CBased on Practice Incentive Program (PIP) data for diabetes, asthma and cervical screening published by the
Medicare Australia website.13
DResearcher estimate, confirmed by study Advisory Group.
EApatient drop-out rate is assumed for the ‘high’ (10%), ‘medium’ (30%) and ‘low’ (50%) scenarios. The yearly
drop-out estimate is pro-rated equally over the 3month, 6month, 9month and 12month follow-up visits. Only
patients who complete the 12 month care program are assigned a health outcome benefit.
FBased on number of practices receiving diabetes outcome payment 2005–2006.13
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Estimates of program benefits
The base-case estimate of program uptake or ‘reach’ was 40%
of patients with stable CHD (Table 2). Therefore, the estimates
of DALYs attributable to CHD and the base-case estimate
of a 15% reduction in DALYs indicate that a total of 15 625
DALYs would be prevented (14 311 DALYs after discounting
by 3%). The higher rate of uptake (65%) would result in 25 716
undiscounted DALYs prevented (discounted by 3%: 23 554),
whereas the lower rate of uptake (21%) would prevent 8271
undiscounted DALYs (discounted by 3%: 7576). ICERs for
lower effectiveness assumptions of 10, 7.5 and 5% are
presented in Fig. 2.
Program costs
The projected net cost of the program was AU$115.66million.
This comprised: $116.23million in patient consultations;
$34.34million in increased pharmaceutical costs; $5.75million
resulting from greater use of imaging and pathology
services; and $19.33million for incentive payments facilitating
program initiation and management. These total costs of
$175.65million are off-set by a potential reduction in costs of
hospital admissions of $59.99million. With the ‘high’ uptake
estimate, total net costs were $160.35million, resulting from
$259.10million in gross costs and $98.74million in savings
from reduced clinical events; whereas the ‘low’ uptake would
lead to a net cost of $75.59million, as a result of $107.35million
in gross costs and a potential saving of $31.7million by reduced
hospitalisations.
Cost effectiveness and sensitivity analysis
Using these base-case estimates of costs, program uptake
and effectiveness results in an incremental cost effectiveness
ratio (ICER) of $8081 per DALY prevented, which is well
below the $50 000 per DALY benchmark currently deemed
acceptable within the Australian health care environment.
Exploring the impact of higher uptake, but lower efficacy
suggests that even with the most conservative estimates of
benefit, such an intervention would provide benefits that
remain well within an acceptable range for health care funding
(Fig. 2). Furthermore, these results represent conservative
estimates as benefits of the program have only been attributed
to patients who have completed all consultations in all the
sensitivity permutations.
Discussion
As a leading source of death and disability, CHD remains
an important target for improving the health of Australians.8
To date, enormous human and financial resources have been
devoted to research and development of effective therapies to
reduce CHD death and disability. Yet, the magnitude of benefit
promised by clinical trial data has not been realised in many
sections of the community, despite the availability of these
proven therapies in current clinical practice.15 The application
of the clinical evidence remains an important limiting step in
translating therapeutic innovation into improvements in patient
outcomes.7,16 Bridging this barrier with a dedicated general
practice-based, goal-oriented program appears very cost-
effective with ICER estimates that are far superior to more
novel therapeutic approaches currently undergoing intense
research.
Acute mortality from CHD continues to decline with
the development and widespread application of acute
pharmacologic and procedural therapies. In contrast, the
chronic burden from this disease is likely to increase. This is,
in part, the result of the emerging epidemic of obesity and
diabetes now faced in Australia, mirroring demographic
patterns seen in many parts of the Western world, combined
with the extended average life expectancy observed among
Australians today.17 Effective management strategies to tackle
the chronic burden of CHD are urgently needed to attenuate the
impact of these demographic trends. Recognition of these needs
has led to substantial research efforts seeking novel therapeutic
agents and strategies targeting newly elucidated disease
$9977$8081$6807
$12 307
$17 062
$14 217
$24 147
$20 354
$17 807
$28 806
$32 626
$38 316
$0
$50 000
LowMediumHigh
Program uptake
15% Effective 10% Effective 7.5% Effective 5% Effective
Fig. 2. Incremental cost-effectiveness ratios for base case estimates and sensitivity analysis based on
variations in effectiveness and program uptake.
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pathways, in the hope of capitalising on such technological
and scientific advances as the decoding of the human genome
and advances in stem cell technology.18,19 Yet, the past 3 decades
of clinical research in cardiology have defined an ample array
of therapeutic options for the treatment of easily identifiable
clinical risk factors and behaviours that account for most of
clinical risk. Recent studies suggest that up to 90% of all first
MIs are accounted for by well established and modifiable
risk factors,20 and that very few (<3%) of all cardiovascular
events occur in patients without any of the traditional risk
factors (smoking, hypertension, diabetes, obesity and
hypercholesterolaemia).21
Therefore, although the promise of novel scientific
discoveries is attractive, substantial gains in health can be
achieved with optimal application of the therapeutic strategies
available to us today. However, the practical issues of
compliance, optimising therapeutic choices in the face of
intolerance to medications, achieving the required lifestyle
modifications and the difficulty of attaining treatment goals for
the management of hypertension, dyslipidaemia and diabetes
potentially explain a large component of the residual risk and
morbidity experiencedbypeoplewithCHD.6,16,22,23These issues
represent obvious missed opportunities for providing clinical
benefits in the ongoing struggle to contain the burden of CHD
in the Australian community.
Although the evidence supporting current recommendations
are robust, it is also recognised that effective implementation of
optimal pharmacologic therapy and lifestyle modification for
secondary prevention is time and resource intensive, and is
therefore often challenging in general practice, where these
activities compete with other priorities. Furthermore, efficacy
often depends on the patient’s initiative and self-motivation in
achieving treatment goals. To date, evidence demonstrating the
effectiveness of integrated programs for the management of
CHD risk have been limited. However, investigators have been
able to demonstrate both effectiveness and cost-effectiveness
of such programs within our local context.22,24,25 Examples in
other areas of chronic management have suggested that
registries enabling the identification of ‘at risk’ individuals, a
comprehensive treatment plan addressing several facets of
management to reduce overall risk and clear treatment goals to
facilitate compliance and long-term lifestyle modification are
key aspects of successful disease management programs as seen
in diabetes. Effective implementation of such a program for
CHD will require dedicated infrastructure and reimbursements
to overcome barriers specific to each practice, with incentive
payments to reward the delivery of quality care. Although
specifically addressing CHD, it would be logical and more
efficient for such a program to build on and integrate with
existing chronic disease payment and incentive initiatives in
general practice such as the Diabetes Practice Incentive
Program, Practice Nurse initiatives, Australian Primary Care
Collaboratives and relevant Chronic Disease Management
(CDM) items. As an initial step, ‘pilot’ programs and possibly
even clinical studies incorporating randomisation clustered by
general practitioner aimed at further defining the uptake and
effectiveness, as well as the costs of such approaches are
urgently required. Furthermore, specific programs evaluating
this strategy among rural and indigenous patients are also
required. Such information would be of vital importance for
refining the assumptions upon which this model is based,
and provide a better assessment of the potential value of this
approach.
Nevertheless, drawing from local data sources, this analysis
suggests that a dedicated general practice-based program for the
management of CHD is potentially very cost-effective, with an
incremental cost-effectiveness ratio that is far superior to many
of the emerging cardiovascular technologies, such as drug-
eluting stents and implantable defibrillators.26,27 Such
observations argue strongly for efforts to build capacity in the
Australian general practice environment to enable chronic
disease management programs. Even when the lowest relative
effectiveness is modelled with the highest program uptake,
these estimates of cost-effectiveness remain below the level
commonly applied to novel pharmacotherapies. However, even
given the extensive burden of CHD currently faced, net costs
of approximately $116million are not inconsequential. Such
estimates only serve to highlight the magnitude of the problem
now faced, and the social and economic imperatives to address
the problem of CHD in Australia.
Limitations
As with the majority of health economic analyses, these
estimates are based on assumptions. Although some data
regarding the uptake of similar programs indicate rates entirely
consistent with those modelled here robust prospective data
demonstrating the benefits and uptake of such a program
would be valuable in refining the cost-effectiveness models
(see http://www.apcc.org.au). However, it should be
acknowledged that this equally applies to all new therapies
and technologies, particularly when these factors are
generalised beyond the clinical trial context, where the relative
efficacy of these novel approaches cannot be assumed.
In addition, care should be taken in the interpretation of direct
cost offsets from the potential reduction in hospitalisations. In
reality, these are not true financial savings, but should be
considered as ‘opportunity costs’.
Finally, whereas ‘myocardial infarction related heart failure’
has been included in the baseline estimates of disease burden,
the efficacy of this program in reducing DALYs and death in
this group of patients is less certain. Nevertheless, among
this high-risk group, efforts to improve compliance and
lifestyle goal attainment are likely to have at least comparable
benefits.
Conclusions
Although innovation in CHD management promises improved
patient outcomes in the future, effective therapies and strategies
for reducing morbidity and mortality are available today.
A general practice-based program for the optimal application
of these strategies and therapies is likely to be very cost-effective
and provide substantial and sustainable benefits to the Australian
community. Further, it is important to note that these promising
cost-effectiveness credentials have been based on a stand-alone
proposal of GPs preparing a CHD care plan as a dedicated
activity. In reality, of course, CHD patients have co-
morbidities (e.g. diabetes) and GPs would be encouraged to
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prepare one comprehensive care plan covering all conditions.
The integration of a new dedicated CHD initiative with the
existing diabetes initiative is a matter requiring careful
consideration with stakeholders. If done correctly, such
integration offers the potential for significant improvements
for CHD patients, while at the same time achieving economies
of scale.
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